-To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC)
and metastatic pancreatic adenocarcinoma (mPAC)
To assess the safety and tolerability of tusamitamab ravtansine
To assess other efficacy parameters of tusamitamab ravtansine
To assess the immunogenicity of tusamitamab ravtansine
The expected duration of study intervention for participants may vary, based on progression
date and the cohort; median expected duration of study per participant is estimated at 8
months for the mBC cohorts and 6 months for the mPAC cohort (up to 1 month for screening, a
median of 4 or 2 months for treatment in the mBC and mPAC cohorts respectively, a median of 1
month for EOT, and follow-up visit 90 days after the last IMP administration).
Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.